Periostin on the road to nonalcoholic fatty liver disease

Polyzos, Stergios A.; Anastasilakis, Athanasios D.

doi:10.1007/s12020-015-0803-7

Cited by 5 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides steatosis, PN has been demonstrated to mediate also hepatic inflammation and fibrosis, probably through both direct and indirect mechanisms related to the concomitant release of pro-inflammatory and pro-fibrotic factors and inhibition of adiponectin, an insulin-sensitizing and anti-inflammatory adipokine. Despite this experimental evidence, there are currently limited data for PN in human NAFLD evolved to NASH or hepatic fibrosis/cirrhosis (which could be expected to present higher PN levels than SS patients) [8,20].…”

Section: Introductionmentioning

confidence: 99%

Periostin Circulating Levels and Genetic Variants in Patients with Non-Alcoholic Fatty Liver Disease

et al. 2020

View full text Add to dashboard Cite

Circulating periostin has been suggested as a possible biomarker in non-alcoholic fatty liver disease (NAFLD) in Asian studies. In the present study, we aimed to test its still controversial relevance in a Caucasian population. In patients with histologically-proven NAFLD (N. = 74; 10 with hepatocellular carcinoma, HCC) plasma periostin concentrations were analyzed. POSTN haplotype analysis was based on rs9603226, rs3829365, and rs1029728. Hepatitis C patients (N. = 81, 7 HCC) and healthy subjects (N. = 27) were used as controls. The median plasma periostin concentration was 11.6 ng/mL without differences amongst groups; it was not influenced by age, liver fibrosis or steatosis. However, possession of haplotype two (rs9603226 = G, rs3829365 = C, rs1028728 = A) was associated with lower circulating periostin compared to other haplotypes. Moreover, periostin was higher in HCC patients. At multivariate analysis, HCC remained the only predictor of high periostin. In conclusion, plasma periostin concentrations in Caucasians NAFLD patients are not influenced by the degree of liver disease, but are significantly higher in HCC. Genetically-determined differences may account for some of the variability. These data suggest extreme caution in predicting a possible future role of periostin antagonists as a rational therapeutic alternative for NAFLD, but show a potential periostin role in the management of NAFLD-associated HCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Periostin Circulating Levels and Genetic Variants in Patients with Non-Alcoholic Fatty Liver Disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…To the best of our knowledge, JPD due to homozygosity for the TNFRSF11B "Balkan mutation" (966_969delTGACinsCTT), resulting in non-functioning osteoprotegerin, has been described in only five patients todate (5). Periostin, a secreted extracellular matrix protein, is expressed in collagen rich connective tissues and interacts with several cell surface integrins, providing signals for tissue development and remodeling (6). Sclerostin, produced almost exclusively by the osteocytes, is a negative regulator of the canonical Wingless (Wnt)/β-catenin signaling, thus inhibiting osteoblastic bone formation (7).…”

Section: Introductionmentioning

confidence: 99%

Periostin and sclerostin levels in juvenile Paget�s disease

Polyzos

Makras

Anastasilakis

et al. 2017

ccmbm

View full text Add to dashboard Cite

SummaryJuvenile Paget's disease (JPD) is a rare, autosomal recessive disorder featuring markedly increased serum alkaline phosphatase activity, indicative of greatly accelerated bone turnover throughout the skeleton. The main aim of this study was to evaluate circulating periostin and sclerostin levels in two adult patients with mild JPD (due to "Balkan" mutation). We measured periostin and sclerostin levels in a previously described woman and a newly diagnosed man with JPD, and 10 apparently healthy individuals, matched (1:5) to JPD patients for gender, age and body mass index. Sclerostin levels were similar between JPD patients and controls. Periostin levels were about 2.5 times higher in JPD patients. Periostin and sclerostin levels were negatively correlated (rs= -0.63; p=0.03). In conclusion, a trend towards higher periostin levels was observed in JPD patients, whereas sclerostin levels were similar to controls.

show abstract